Opendata, web and dolomites

SYNKIT SIGNED

Synthetic Natural Killer Cells for Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SYNKIT project word cloud

Explore the words cloud of the SYNKIT project. It provides you a very rough idea of what is the project "SYNKIT" about.

host    combat    pave    disarming    strategy    engineering    function    allogenicity    missing    efficacy    recognition    education    antigen    tumours    setting    rejection    underlying    generation    attractive    triggers    vitro    cancer    tailor    immune    shelf    ipscs    stem    molecular    eliminate    lack    insights    self    option    ipsc    infusion    killer    nk    leukocyte    mechanism    recipient    pluripotent    natural    laboratory    hla    persistence    limited    successful    ligands    intrinsic    engineered    cells    introduction    capacity    tumour    escape    therapies    off    transferred    complete    reduce    completion    ink    limitations    modulate    thereby    anti    transfer    absence    unravelled    allogeneic    broad    synthetic    genetic    immunotherapy    poor    cell    platform    worldwide    synkit    possess    differentiation    ing    functional    diminishing    human    modulates    deficient    deletion    prevent    innovative    impaired    bottlenecks    expand    urging    death    treatment   

Project "SYNKIT" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 191˙852 €
 EC max contribution 191˙852 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-07-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 191˙852.00

Map

 Project objective

'Cancer remains a leading cause of death worldwide, urging for innovative therapies. Infusion of natural killer (NK) cells, which possess an intrinsic capacity to eliminate cancer cells, is a promising treatment option for various tumours. Genetic engineering of NK cells before transfer allows to specifically tailor and modulate their anti-tumour responses. One particularly attractive strategy for broad implementation of NK cell immunotherapy in an “off-the-shelf” setting is to expand large numbers of NK cells from induced pluripotent stem cells (iPSCs). However, this approach is limited by two main bottlenecks: i) poor persistence of allogeneic iPSC-derived NK (iNK) cells due to rejection by the recipient immune system and ii) impaired functionality due to failure to achieve complete differentiation in vitro. The SYNKIT project seeks to address both of these current limitations through genetic engineering of iNK cells for increased persistence and function. Deletion of human leukocyte antigen (HLA) 'self-ligands' allows the transferred cells to escape from host T cells. However, absence of HLA also triggers “missing-self” recognition and rejection by host NK cells. In addition, new insights from the host laboratory into the molecular mechanism underlying NK cell education have unravelled a pathway of functional disarming in NK cells that lack self-ligands, further diminishing the anti-tumour efficacy of HLA-deficient NK cells. In SYNKIT, I will use HLA-deficient iNK cells as a platform to assess how introduction of synthetic self-ligands modulates the allogenicity and functionality of iNK cells. The overall goal of SYNKIT is to identify synthetic self-ligands, which reduce recognition by the host immune system and yet prevent functional disarming of the engineered iNK cells, thereby resulting in optimised anti-tumour function. Successful completion of SYNKIT will pave the way for development of next generation immunotherapy to more effectively combat cancer. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SYNKIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SYNKIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

XmonMASER (2019)

Josephson maser and heat transport in dissipative open quantum systems

Read More  

Transcendence (2019)

The Nature of Transcendence

Read More  

BrownianReactivation (2019)

Neural stochasticity and criticality in memory replay

Read More  
lastchecktime (2020-07-14 21:52:28) correctly updated